ROCHE's HIVID APPROVED FOR MONOTHERAPY IN HIV-INFECTED PATIENTS; NEW INDICATIONS FOR COMBINATION THERAPY WITH RETROVIR COME UNDER ACCELERATED APPROVAL
Executive Summary
Roche's Hivid is approved for second-line monotherapy in HIV- infected patients who experience disease progression with zidovudine treatment or who are intolerant to zidovudine. The new indication was approved Aug. 5.
You may also be interested in...
Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials
Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials
AstraZeneca To Revisit Iressa Dosing Following Failed Survival Study
Inappropriate dose selection is one issue AstraZeneca will examine following Iressa's failure to demonstrate a survival benefit in a Phase IV trial in refractory non-small cell lung cancer, CEO Tom McKillop indicated